Strategic Acquisition Meridian Life Science unit acquired Bioline, strengthening its immuno- and molecular test materials portfolio. This presents a sales opportunity to cross-sell expanded reagent lines, kits, and raw materials to Meridian’s existing diagnostics and life science customers.

Broad Product Portfolio Over 300 proprietary and non-proprietary reagents and kits and a focus on ultra-pure dNTPs and enzymes offer multiple entry points for upsell across molecular biology, cell analysis, nucleic acid separation, and protein purification workflows.

Manufacturing Footprint Large-scale manufacturing capability within Meridian Life Science enables consistent supply and potential private-label or co-branded opportunities for academic labs and biotechs seeking reliable sourcing of high-quality reagents.

Quality and Compliance ISO 13485 quality system positioning supports sales to medical and clinical development customers requiring regulated, high-purity reagents, appealing to diagnostic and translational research partners.

Market Reach Existing relationships with Canadian growers and diverse sectors (biotech, agriculture, forensic, environmental) indicate a channel to expand into new geographies and industry segments through Meridian’s global network.